JE
MCID: JPN002
MIFTS: 61

Japanese Encephalitis (JE)

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Japanese Encephalitis

MalaCards integrated aliases for Japanese Encephalitis:

Name: Japanese Encephalitis 12 73 20 58 3 15 17 70 32
Je 20 3
Japanese B Encephalitis 12
Encephalitis, Japanese 44
Encephalitis Japanese 54

Characteristics:

Orphanet epidemiological data:

58
japanese encephalitis
Inheritance: Not applicable; Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare infectious diseases


Summaries for Japanese Encephalitis

CDC : 3 Japanese encephalitis (JE) virus is the leading cause of vaccine-preventable encephalitis in Asia and the western Pacific. For most travelers to Asia, the risk for JE is very low but varies based on destination, length of travel, season, and activities. Most people infected with JE do not have symptoms or have only mild symptoms. However, a small percentage of infected people develop inflammation of the brain (encephalitis), with symptoms including sudden onset of headache, high fever, disorientation, coma, tremors and convulsions. About 1 in 4 cases are fatal. To prevent getting sick from JE, use an EPA-registered insect repellent, wear long-sleeved shirts and long pants, and get vaccinated.

MalaCards based summary : Japanese Encephalitis, also known as je, is related to west nile virus and zika fever, and has symptoms including headache, coma and tremors. An important gene associated with Japanese Encephalitis is CD209 (CD209 Molecule), and among its related pathways/superpathways are Innate Immune System and Viral mRNA Translation. The drugs Ethanol and Immunoglobulins, Intravenous have been mentioned in the context of this disorder. Affiliated tissues include brain, kidney and t cells, and related phenotypes are encephalitis and fever

Disease Ontology : 12 A viral infectious disease that results in infection located in brain, has material basis in Japanese encephalitis virus, which is transmitted by Culex tritaeniorhynchus mosquito bite. The infection has symptom headache, has symptom high fever, has symptom neck stiffness, has symptom stupor, has symptom disorientation, has symptom coma, has symptom tremors, has symptom convulsions, and has symptom spastic paralysis.

Wikipedia : 73 Japanese encephalitis (JE) is an infection of the brain caused by the Japanese encephalitis virus (JEV).... more...

Related Diseases for Japanese Encephalitis

Diseases related to Japanese Encephalitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 355)
# Related Disease Score Top Affiliating Genes
1 west nile virus 31.7 SPCS1 RSAD2 IRF3 IFNA1 DDX58 CLEC4M
2 zika fever 31.7 TLR3 STAT2 DDX58 CD209
3 dengue virus 30.9 TNF STAT2 SPCS1 RSAD2 IVNS1ABP DDX58
4 viral encephalitis 30.8 TNF TLR3 IFNB1 IFNA1 CXCL10 CCL5
5 encephalitis 30.8 TRIM52 TNF TLR3 SPCS1 RSAD2 IRF3
6 meningoencephalitis 30.7 TNF CXCL10 CCL5
7 yellow fever 30.5 STAT1 SPCS1 RSAD2 IFNB1 DDX58 CXCL10
8 rubella 30.5 TNF TLR3 IFNB1 DDX58
9 dengue disease 30.4 TNF IVNS1ABP IFNB1 IFNA1 CD209 CCL5
10 hepatitis a 30.4 TNF TLR3 IFNA1
11 west nile encephalitis 30.3 TLR7 CLEC4M
12 poliomyelitis 30.3 TNF TLR3 IFNA1 DDX58
13 vaccinia 30.3 TNF STAT2 STAT1 IRF3 IFNB1 IFNA1
14 stomatitis 30.3 TNF RSAD2 IFNB1 IFNA1 DDX58
15 eastern equine encephalitis 30.2 IFNA1 CLEC4M CD209
16 hepatitis c virus 30.2 SPCS1 RSAD2 IRF3 DDX58 CLEC4M
17 disease by infectious agent 30.1 TNF TLR7 IFNB1 IFNA1 CLEC4M CD209
18 west nile fever 30.1 IRF3 IFNA1 CXCL10 CLEC4M CD209
19 diarrhea 30.1 TNF STAT1 IFNB1 IFNA1
20 hepatitis e 30.0 TNF TLR3 IFNB1 DDX58
21 allergic disease 30.0 TNF TLR7 CXCL10 CCL5
22 respiratory failure 30.0 TNF CXCL10 CCL5 CCL2
23 tick-borne encephalitis 29.9 TLR3 RSAD2 IVNS1ABP IFNB1 IFNA1 DDX58
24 swine influenza 29.8 TNF IRF3 IFNB1 IFNA1 DDX58
25 chickenpox 29.8 TNF STAT1 IFNB1 IFNA1
26 chikungunya 29.7 TNF TLR7 STAT1 RSAD2 DDX58 CD209
27 bacterial infectious disease 29.7 TNF TLR3 IFNB1 CCL2
28 hepatitis b 29.6 TNF TLR3 STAT1 IFNB1 IFNA1
29 hepatitis 29.5 TNF RSAD2 IRF3 IFNA1 DDX58 CXCL10
30 rabies 29.5 TLR3 STAT2 STAT1 IRF3 IFNA1 DDX58
31 avian influenza 29.4 TNF STAT2 IVNS1ABP IFNA1 DDX58 CXCL10
32 herpes simplex 29.4 TLR3 STAT2 STAT1 IRF3 IFNB1 IFNA1
33 mumps 29.4 TNF TLR3 STAT2 STAT1 IFNB1 IFNA1
34 dengue shock syndrome 29.3 TNF STAT2 IVNS1ABP IFNA1 CLEC4M CD209
35 dengue hemorrhagic fever 29.2 TNF TLR7 TLR3 STAT2 STAT1 IFNB1
36 venezuelan equine encephalitis 29.2 STAT2 STAT1 IFNB1 IFNA1 CXCL10 CCL2
37 newcastle disease 29.1 TNF TLR3 IVNS1ABP IRF3 IFNB1 IFNA1
38 mouth disease 29.0 TLR7 TLR3 STAT1 IRF3 IFNA1 DDX58
39 thrombocytopenia 28.9 TNF TLR7 STAT2 STAT1 IFNB1 IFNA1
40 measles 28.9 TNF TLR7 TLR3 STAT2 STAT1 IRF3
41 hepatitis c 28.8 TNF TLR3 STAT1 RSAD2 IRF3 IFNB1
42 immune deficiency disease 28.7 TNF STAT1 IRF3 IFNB1 IFNA1 CXCL10
43 influenza 28.1 TNF TLR7 TLR3 STAT1 RSAD2 IVNS1ABP
44 viral infectious disease 27.7 TNF TLR7 TLR3 STAT2 STAT1 IVNS1ABP
45 st. louis encephalitis 11.2
46 neuroblastoma 10.5
47 ocular motor apraxia 10.5
48 murray valley encephalitis 10.4
49 scorpion envenomation 10.4 TNF CCL5
50 movement disease 10.4

Graphical network of the top 20 diseases related to Japanese Encephalitis:



Diseases related to Japanese Encephalitis

Symptoms & Phenotypes for Japanese Encephalitis

Human phenotypes related to Japanese Encephalitis:

58 31 (show top 50) (show all 84)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 encephalitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002383
2 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
3 increased intracranial pressure 58 31 frequent (33%) Frequent (79-30%) HP:0002516
4 vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002013
5 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
6 skeletal muscle atrophy 58 31 frequent (33%) Frequent (79-30%) HP:0003202
7 mask-like facies 58 31 frequent (33%) Frequent (79-30%) HP:0000298
8 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
9 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
10 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
11 decreased motor nerve conduction velocity 58 31 frequent (33%) Frequent (79-30%) HP:0003431
12 distal lower limb muscle weakness 58 31 frequent (33%) Frequent (79-30%) HP:0009053
13 functional motor deficit 58 31 frequent (33%) Frequent (79-30%) HP:0004302
14 cogwheel rigidity 58 31 frequent (33%) Frequent (79-30%) HP:0002396
15 neutrophilia 58 31 frequent (33%) Frequent (79-30%) HP:0011897
16 facial grimacing 58 31 frequent (33%) Frequent (79-30%) HP:0000273
17 increased circulating igm level 58 31 frequent (33%) Frequent (79-30%) HP:0003496
18 emg: chronic denervation signs 58 31 frequent (33%) Frequent (79-30%) HP:0003444
19 hyperintensity of mri t2 signal of the spinal cord 58 31 frequent (33%) Frequent (79-30%) HP:0040272
20 increased csf protein 58 31 frequent (33%) Frequent (79-30%) HP:0002922
21 weakness due to upper motor neuron dysfunction 58 31 frequent (33%) Frequent (79-30%) HP:0010549
22 csf lymphocytic pleiocytosis 58 31 frequent (33%) Frequent (79-30%) HP:0200149
23 paucity of anterior horn motor neurons 58 31 frequent (33%) Frequent (79-30%) HP:0007277
24 focal t2 hyperintense thalamic lesion 58 31 frequent (33%) Frequent (79-30%) HP:0012692
25 bilateral tonic-clonic seizure 31 frequent (33%) HP:0002069
26 nystagmus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000639
27 facial palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0010628
28 behavioral abnormality 58 31 occasional (7.5%) Occasional (29-5%) HP:0000708
29 cognitive impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0100543
30 intellectual disability, severe 58 31 occasional (7.5%) Occasional (29-5%) HP:0010864
31 myoclonus 58 31 occasional (7.5%) Occasional (29-5%) HP:0001336
32 genu recurvatum 58 31 occasional (7.5%) Occasional (29-5%) HP:0002816
33 elbow flexion contracture 58 31 occasional (7.5%) Occasional (29-5%) HP:0002987
34 talipes equinovarus 58 31 occasional (7.5%) Occasional (29-5%) HP:0001762
35 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
36 hyponatremia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002902
37 abnormality of extrapyramidal motor function 58 31 occasional (7.5%) Occasional (29-5%) HP:0002071
38 dystonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001332
39 meningitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001287
40 status epilepticus 58 31 occasional (7.5%) Occasional (29-5%) HP:0002133
41 choreoathetosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001266
42 coma 58 31 occasional (7.5%) Occasional (29-5%) HP:0001259
43 respiratory distress 58 31 occasional (7.5%) Occasional (29-5%) HP:0002098
44 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
45 excessive salivation 58 31 occasional (7.5%) Occasional (29-5%) HP:0003781
46 muscle flaccidity 58 31 occasional (7.5%) Occasional (29-5%) HP:0010547
47 opsoclonus 58 31 occasional (7.5%) Occasional (29-5%) HP:0010543
48 distal upper limb muscle weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0008959
49 respiratory paralysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002203
50 focal motor seizure 58 31 occasional (7.5%) Occasional (29-5%) HP:0011153

Symptoms:

12
  • headache
  • coma
  • tremors
  • disorientation
  • convulsions
  • neck stiffness
  • high fever
  • stupor
  • spastic paralysis

GenomeRNAi Phenotypes related to Japanese Encephalitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.86 CCL2
2 Decreased viability GR00221-A-4 9.86 CCL2
3 Decreased viability GR00249-S 9.86 IFIT2 TLR3
4 Decreased viability GR00342-S-1 9.86 TLR3
5 Decreased viability GR00342-S-2 9.86 TLR3
6 Decreased viability GR00386-A-1 9.86 CCL2 CLEC4M IFNB1 IVNS1ABP STAT2
7 Decreased viability GR00402-S-2 9.86 CCL2 SPCS1 TLR3 TNF TRIM52
8 Increased the percentage of infected cells GR00402-S-1 8.32 TLR3

MGI Mouse Phenotypes related to Japanese Encephalitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 CCL5 CD209 CLEC4G CLEC4M CXCL10 DDX58
2 homeostasis/metabolism MP:0005376 9.83 CD209 CLEC4G CLEC4M CXCL10 DDX58 IFIT2
3 immune system MP:0005387 9.5 CCL2 CCL5 CLEC4G CLEC4M CXCL10 DDX58

Drugs & Therapeutics for Japanese Encephalitis

Drugs for Japanese Encephalitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2 Immunoglobulins, Intravenous Phase 4
3 Immunologic Factors Phase 4
4 Antibodies Phase 4
5 Antibodies, Blocking Phase 4
6 Immunoglobulins Phase 4
7 Vaccines Phase 4
8 Orange Approved Phase 3
9
Lactitol Approved, Investigational Phase 3 585-86-4 157355
10
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
11 Protective Agents Phase 3
12 Insect Repellents Phase 3
13 Pharmaceutical Solutions Phase 3
14 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
15
Ribavirin Approved Phase 2 36791-04-5 37542
16 Anti-Infective Agents Phase 2
17 Antiviral Agents Phase 2
18 Antimetabolites Phase 2
19 gamma-Globulins Phase 2
20 Rho(D) Immune Globulin Phase 2
21
Aluminum sulfate Approved Phase 1 10043-01-3

Interventional clinical trials:

(show top 50) (show all 76)
# Name Status NCT ID Phase Drugs
1 Assessment of Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With a Single Dose of JE-CV Unknown status NCT01954810 Phase 4
2 The Safety and Immunogenicity of Enterovirus Type 71 Inactivated Vaccine (Human Diploid Cell) With Two Measles Attenuated Live Vaccine and Live Attenuated Japanese Encephalitis Vaccine at the Same Time Point in Infants (8-month-old) Unknown status NCT03296410 Phase 4
3 A Clinical Trial in Healthy Infants to Assess Lot-to-lot Consistency of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Non-inferiority With Respect to an Earlier Product. Completed NCT01567865 Phase 4
4 A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2 Completed NCT01656200 Phase 4
5 Assessment of the Immunogenicity and Safety of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine in Children in Sri Lanka Completed NCT00463684 Phase 4
6 A Study to Evaluate the Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine Completed NCT01815073 Phase 4
7 Assessment of the Immunogenicity and Safety of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine in Children in Sri Lanka Completed NCT00463476 Phase 4
8 An Open-label, Uncontrolled Phase 4 Study to Assess the Safety and Immunogenicity of the Japanese Encephalitis (JE) Vaccine Ixiaro® (IC51) in an Elderly Population Completed NCT01158599 Phase 4
9 A Multi-center, Open, phase4 Study to Assess the Long-term Immunogenicity and Safety of Fourth Administration of BR JEV and to Investigate on Vaccine Interchangeability in Children Aged 6 Years Who Received 3 Doses With ENCEVAC or JEV-GCC Completed NCT02532569 Phase 4
10 Post-licensure, Phase IV, Safety Study of IMOJEV® in Thailand Completed NCT01981967 Phase 4
11 Assessment of Long Term Immunogenicity of Japanese Encephalitis Live Attenuated SA-14-14-2 Vaccine in Previously Vaccinated Bangladeshi Children and Antibody Response and Safety to a Booster Dose Completed NCT02514746 Phase 4
12 Immunogenicity and Safety of Concurrent Administration of Live, Attenuated SA 14-14-2 Japanese Encephalitis Vaccine and Measles-Mumps-Rubella Vaccine in Infants 9-12 Months of Age in the Philippines Completed NCT02880865 Phase 4
13 Characterisation of Cellular and Humoral Immunity in Elderly People After Immunization With a Purified, Inactivated Japanese Encephalitis Vaccine. Completed NCT01398540 Phase 4
14 Neutralizing Antibody Titers 6 Years After the Third Dose of Inactivated Japanese Encephalitis Vaccine and Projected Duration of Protection Completed NCT02039440 Phase 4
15 Immunogenicity of Co-administration of Measles Containing Vaccine and Japanese Encephalitis Alive Vaccines Completed NCT02643433 Phase 4
16 Immunogenicity of a Live Attenuated Chimeric Japanese Encephalitis Vaccine (IMOJEV) as a Booster Dose After a Primary Vaccination With CD.JEVAX in Thai Children Completed NCT02526550 Phase 4
17 A Clinical Trial in Healthy Infants to Assess Lot-to-lot Consistency of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine Manufactured in a New Good Manufacturing Practices Facility and Non-inferiority With Respect to an Earlier Product. Completed NCT01635816 Phase 4
18 Characterisation of Cellular and Humoral Immune Responses Following the First Booster Immunisation With the Inactivated, Purified Japanese Encephalitis Vaccine IXIARO® in Elderly Compared to Young Individuals. Recruiting NCT03971058 Phase 4
19 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Measles, Mumps, and Rubella Combined Live Attenuated Vaccine/ Encephalitis Live Attenuated Vaccine Recruiting NCT04111432 Phase 4
20 Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province, China: An Open-labeled, Ambidirectional Cohort Study Enrolling by invitation NCT04817917 Phase 4
21 Clinical Evaluation of Insect Repellent and Insecticide Treated Nets Against Malaria, JE & Dengue in Rural Communities in Lao PDR Unknown status NCT00938379 Phase 3 20% deet insect repellent;placebo control
22 A Single-centre Phase III Clinical Trial for Vero Cell-derived Inactivated Japanese Encephalitis Vaccine Produced by Shandong Hengye Biotech Co., Ltd. in Healthy Chinese Infants Aged 6-11 Months, Aimed to Evaluate Immunogenicity and Safety Completed NCT02367664 Phase 3
23 Assessment of the Non-Inferiority of the Concurrent Administration of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Measles Vaccine Given Alone Completed NCT00249769 Phase 3
24 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults Completed NCT01466387 Phase 3
25 A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Separately According to 1 of 2 Different Preexposure Prophylaxis Schedules to Healthy Adult Subjects. Completed NCT01662440 Phase 3
26 Assessment of the Memory Immune Response, Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With a Single Dose of JE-CV and Long-Term Follow-Up Completed NCT01190228 Phase 3
27 Long Term Immunity and Safety Following Vaccination With the Japanese Encephalitis Vaccine IC51(IXIARO®, JESPECT®) In a Pediatric Population in Non Endemic Countries. Uncontrolled, Phase 3 Follow-up Study Completed NCT01246479 Phase 3
28 A Multicentre, Randomized, Double-blind, Phase III Study of The Comparative Immunogenicity, Safety and Tolerability of Two Japanese Encephalitis Vaccines (ChimeriVax™-JE and JE-VAX®) Completed NCT00314145 Phase 3
29 Immunogenicity and Safety of a Single Primary Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) Given to Healthy Subjects in Vietnam Completed NCT02492165 Phase 3
30 Immunogenicity and Safety Exploration of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) Given One Year After Primary Immunization in Healthy Children in South Korea Completed NCT01900444 Phase 3
31 A Multi-center, Active-control, Randomized, Double-blind Phase 3 Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived Inactivated Japanese Encephalitis Vaccine 'KD-287(JEIMMUGEN INJ.) in Korean Healthy Children Aged 12~23 Months Completed NCT01150942 Phase 3
32 Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE CV) Concomitantly Administered With Measles, Mumps, and Rubella (MMR) Vaccine in Toddlers in Taiwan. Completed NCT01188343 Phase 3
33 Safety and Tolerability of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Placebo Controlled Phase 3 Study Completed NCT00605085 Phase 3
34 Observer Blinded, Randomized Phase 3 Study to Investigate the Non-Inferiority of IC51 vs. JE-VAX as Vaccines for Japanese Encephalitis in Healthy Subjects Completed NCT00604708 Phase 3
35 Safety and Immunogenicity of Concomitant Vaccination With IC51 and HARVIX® 1440 in Healthy Subjects. A Single-blind Randomized, Controlled Phase 3 Study Completed NCT00596271 Phase 3
36 Phase 3 Study to Compare a Rapid Immunization Regime With the Standard Regime of IC51 as Vaccine for Japanese Encephalitis Completed NCT00595790 Phase 3
37 Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Controlled Phase 3 Study. Completed NCT00595465 Phase 3
38 Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 on Long Term Immunogenicity. An Uncontrolled, Open-label Phase 3 Study. Completed NCT00595309 Phase 3
39 Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 Completed NCT00595270 Phase 3
40 Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Controlled Phase 3 Study. Completed NCT00594958 Phase 3
41 Immunogenicity of a Commercial Batch of the Japanese Encephalitis Vaccine IC51 up to Twenty-four Months Post Filling. An Open-label, Multicenter, Phase 3 Study Completed NCT00776230 Phase 3
42 Ability of the New Vero-cell-derived Inactivated Japanese Encephalitis Vaccine (IXIARO) to Elicit a Booster Response in Travellers Previously Vaccinated With Traditional Mouse-brain Derived Vaccine (JE-MB) Completed NCT01386827 Phase 3
43 Evaluate the Safety and Immunogenicity of a Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) Produced by VABIOTECH (Vietnam) in Vietnamese Children Aged 9-24 Months Completed NCT03282370 Phase 3
44 Long-Term Immunity and Safety With or Without a Booster Dose Following Primary Vaccination With the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population in a JEV-Endemic Country. Open-Label, Randomized, Phase 3 Study Completed NCT01296360 Phase 3
45 Lot-to-lot Consistency, Bridging, and Safety Trial of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines Completed NCT00735644 Phase 3
46 Immunogenicity and Safety of a Single Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) in Comparison With a Single Dose of SA14-14-2 Vaccine (CD.JEVAX™, Chengdu Institute of Biological Products, China) Administered in Healthy Toddlers in South-Korea Completed NCT01396512 Phase 3
47 Long-Term Assessment at 24 Months Post-Vaccination of the Non-Inferiority of the Concurrent Administration of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Measles Vaccine to Measles Vaccine Given Alone Completed NCT00412516 Phase 3
48 Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children Completed NCT01408537 Phase 3
49 A Controlled Study of the Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Comparison With SA14-14-2 Vaccine in Infants and Toddlers in Thailand Completed NCT01092507 Phase 3
50 Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population. Open Label, Randomized, Active Controlled, Phase 3 Study Completed NCT01041573 Phase 3

Search NIH Clinical Center for Japanese Encephalitis

Cochrane evidence based reviews: encephalitis, japanese

Genetic Tests for Japanese Encephalitis

Anatomical Context for Japanese Encephalitis

The Foundational Model of Anatomy Ontology organs/tissues related to Japanese Encephalitis:

19
Brain

MalaCards organs/tissues related to Japanese Encephalitis:

40
Brain, Kidney, T Cells, Spinal Cord, Skeletal Muscle, Caudate Nucleus, Pons

Publications for Japanese Encephalitis

Articles related to Japanese Encephalitis:

(show top 50) (show all 5331)
# Title Authors PMID Year
1
Mechanism and specificity of a symmetrical benzimidazolephenylcarboxamide helicase inhibitor. 54 61
20108979 2010
2
Structure-based virtual screening for novel inhibitors of Japanese encephalitis virus NS3 helicase/nucleoside triphosphatase. 54 61
19863664 2010
3
Understanding helicases as a means of virus control. 61 54
16611118 2006
4
Development and evaluation of an enzyme-linked immunosorbent assay for quantifying antibodies to Japanese encephalitis virus nonstructural 1 protein to detect subclinical infections in vaccinated horses. 61 54
15528700 2004
5
Ring-expanded ("fat") nucleoside and nucleotide analogues exhibit potent in vitro activity against flaviviridae NTPases/helicases, including those of the West Nile virus, hepatitis C virus, and Japanese encephalitis virus. 54 61
12954067 2003
6
Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses. 54 61
12694177 2003
7
Antibody to the nonstructural protein NS1 of Japanese encephalitis virus: potential application of mAb-based indirect ELISA to differentiate infection from vaccination. 54 61
11166901 2001
8
Detection of flaviviruses by reverse transcriptase-polymerase chain reaction with the universal primer set. 54 61
9130232 1997
9
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage. 61
33724154 2021
10
A comparative genomics-based study of positive strand RNA viruses emphasizing on SARS-CoV-2 utilizing dinucleotide signature, codon usage and codon context analyses. 61
33615042 2021
11
Phrenic nerve palsy in Japanese encephalitis: a rare association. 61
32638271 2021
12
Structural and biochemical insights into flavivirus proteins. 61
33607183 2021
13
Use of seroprevalence to guide dengue vaccination plans for older adults in a dengue non-endemic country. 61
33793562 2021
14
Immunogenicity and safety of the third booster dose of the inactivated Japanese encephalitis vaccine in Korean children: A prospective multicenter study. 61
33712352 2021
15
Japanese encephalitis virus manipulates lysosomes membrane for RNA replication and utilizes autophagy components for intracellular growth. 61
33725516 2021
16
Cerebral cysticercosis in a wild Bengal tiger (Panthera tigris tigris) in Bhutan: A first report in non-domestic felids. 61
33665082 2021
17
Computational identification of natural product leads that inhibit mast cell chymase: an exclusive plausible treatment for Japanese encephalitis. 61
32036760 2021
18
Host-Feeding Preference and Diel Activity of Mosquito Vectors of the Japanese Encephalitis Virus in Rural Cambodia. 61
33800999 2021
19
Dogs as Sentinels for Flavivirus Exposure in Urban, Peri-Urban and Rural Hanoi, Vietnam. 61
33808552 2021
20
Pathogenesis and shedding of Usutu virus in juvenile chickens. 61
33769213 2021
21
MiR-4448 is involved in deltamethrin resistance by targeting CYP4H31 in Culex pipiens pallens. 61
33726813 2021
22
Unique structural features of flaviviruses' capsid proteins: new insights on structure-function relationship. 61
33721656 2021
23
RNAi screening reveals requirement for PDGFRβ in JEV infection. 61
33753340 2021
24
The Effect of a TLR4 Agonist/Cationic Liposome Adjuvant on Varicella-Zoster Virus Glycoprotein E Vaccine Efficacy: Antigen Presentation, Uptake, and Delivery to Lymph Nodes. 61
33804176 2021
25
Health problems in travellers to Nepal visiting CIWEC clinic in Kathmandu - A GeoSentinel analysis. 61
33639265 2021
26
Strategies for Ensuring Required Service Level for COVID-19 Herd Immunity in Indian Vaccine Supply Chain. 61
33776195 2021
27
Japanese Encephalitis in China in the Period of 1950-2018: From Discovery to Control. 61
33766213 2021
28
Temperate conditions restrict Japanese encephalitis virus infection to the mid-gut and prevents systemic dissemination in Culex pipiens mosquitoes. 61
33731761 2021
29
Changes in Rice and Livestock Production and the Potential Emergence of Japanese Encephalitis in Africa. 61
33806470 2021
30
Autoimmune encephalitis after Japanese encephalitis in children: A prospective study. 61
33773410 2021
31
DHA attenuated Japanese Encephalitis virus infection-induced neuroinflammation and neuronal cell death in cultured rat Neuron/glia. 61
33486004 2021
32
Valosin-containing protein/p97 plays critical roles in the Japanese encephalitis virus life cycle. 61
33731458 2021
33
Immunogenicity of Vero Cell Culture-derived Japanese Encephalitis Vaccine in Pediatric and Young Hematopoietic Stem Cell Transplantation Recipients. 61
33427799 2021
34
Japanese encephalitis vaccine cost: a major reason to be vaccinated in Bali. 61
33772281 2021
35
Natural chemical entities from Arisaema genus might be a promising break-through against Japanese encephalitis virus infection: a molecular docking and dynamics approach. 61
32072856 2021
36
Current Status and a Perspective of Mosquito-Borne Diseases in the Republic of Korea. 61
33136531 2021
37
Ketoacidotic crisis after vaccination in a girl with beta-ketothiolase deficiency: a case report. 61
33708533 2021
38
The ESCRT-I Subunit Tsg101 Plays Novel Dual Roles in Entry and Replication of Classical Swine Fever Virus. 61
33328308 2021
39
The abundance of Culex mosquito vectors for West Nile Virus and other flaviviruses: A time-series analysis of rainfall and temperature dependence in Singapore. 61
33254953 2021
40
Positive Feedback Loop of Long Noncoding RNA OASL-IT1 and Innate Immune Response Restricts the Replication of Zika Virus in Epithelial A549 Cells. 61
33626545 2021
41
Antibody-dependent enhancement (ADE) of dengue virus: Identification of the key amino acid that is vital in DENV vaccine research. 61
33217097 2021
42
[Expert consensus on informed consent for vaccination (part one)]. 61
33548950 2021
43
[Expert consensus on informed consent for vaccination(Part One)]. 61
33548951 2021
44
Monoclonal Antibody That Inhibits Cleavage Activity of Japanese Encephalitis Virus NS3. 61
33625288 2021
45
Pre-treatment with Scopolamine Naturally Suppresses Japanese Encephalitis Viral Load in Embryonated Chick Through Regulation of Multiple Signaling Pathways. 61
33620666 2021
46
Shape relatedness between geographic populations of Culex tritaeniorhynchus, the primary vector of Japanese encephalitis virus: A landmark study. 61
33581329 2021
47
Mosquito defensin facilitates Japanese encephalitis virus infection by downregulating the C6/36 cell-surface antiviral protein HSC70B. 61
33385886 2021
48
CD8+ T cells are crucial for humoral immunity establishment by SA14-14-2 live attenuated Japanese encephalitis vaccine in mice. 61
32749679 2021
49
Axl Alleviates Neuroinflammation and Delays Japanese Encephalitis Progression in Mice. 61
33534086 2021
50
Potential Role of Birds in Japanese Encephalitis Virus Zoonotic Transmission and Genotype Shift. 61
33668224 2021

Variations for Japanese Encephalitis

Expression for Japanese Encephalitis

Search GEO for disease gene expression data for Japanese Encephalitis.

Pathways for Japanese Encephalitis

Pathways related to Japanese Encephalitis according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 TNF TLR7 TLR3 STAT2 STAT1 RSAD2
2
Show member pathways
13.81 TNF TLR7 TLR3 STAT2 STAT1 SPCS1
3
Show member pathways
13.4 TNF TLR7 TLR3 STAT2 STAT1 CXCL10
4
Show member pathways
13.26 TNF STAT2 STAT1 RSAD2 IRF3 IFNB1
5
Show member pathways
13.01 TNF TLR3 STAT2 STAT1 IRF3 IFNB1
6
Show member pathways
12.96 TNF TLR7 TLR3 STAT2 STAT1 RSAD2
7
Show member pathways
12.93 TNF TLR3 STAT2 STAT1 IRF3 IFNB1
8
Show member pathways
12.84 STAT2 STAT1 CXCL10 CCL5 CCL2
9
Show member pathways
12.75 TNF TLR7 TLR3 STAT1 IRF3 IFNB1
10 12.72 TNF TLR3 STAT2 STAT1 IRF3 IFNB1
11
Show member pathways
12.57 TNF IRF3 IFNB1 IFNA1 DDX58 CXCL10
12
Show member pathways
12.56 TLR3 IRF3 IFNB1 IFNA1 DDX58 CXCL10
13
Show member pathways
12.5 STAT2 STAT1 RSAD2 IRF3 IFNB1 IFNA1
14
Show member pathways
12.37 STAT2 STAT1 IFNB1 IFNA1
15 12.36 TNF IRF3 IFNB1 CCL5
16
Show member pathways
12.3 TNF CXCL10 CCL5 CCL2
17
Show member pathways
12.29 TNF TLR7 TLR3 IRF3 IFNB1
18 12.29 TNF STAT1 IFNB1 IFNA1 CLEC4M CD209
19
Show member pathways
12.27 TNF TLR3 STAT1 IRF3
20
Show member pathways
12.27 TNF STAT2 STAT1 RSAD2 IRF3 IFNB1
21
Show member pathways
12.25 TNF STAT2 STAT1 CLEC4M CD209
22 12.25 TNF TLR7 TLR3 STAT2 STAT1 RSAD2
23
Show member pathways
12.22 TNF TLR7 STAT1 IFNB1 CXCL10
24
Show member pathways
12.21 TNF TLR7 TLR3 STAT2 STAT1 RSAD2
25
Show member pathways
12.2 TNF TLR3 STAT2 STAT1 IFNB1 IFNA1
26 12.17 TNF TLR7 TLR3 STAT1
27 12.12 TNF STAT2 STAT1 IRF3 IFNB1 IFNA1
28 12.08 TNF IRF3 IFNB1 CCL2
29 12.05 TNF STAT2 STAT1 IFNB1
30 12.02 TNF IFNB1 CXCL10 CCL5 CCL2
31 11.89 STAT2 STAT1 IFNB1 IFNA1
32 11.86 TNF STAT1 CCL2
33
Show member pathways
11.83 TNF TLR7 TLR3 STAT2 STAT1
34 11.82 TNF CCL5 CCL2
35
Show member pathways
11.81 TLR7 TLR3 STAT1
36 11.79 TNF TLR7 IFNB1 CD209
37 11.63 TNF CCL5 CCL2
38 11.58 TNF CXCL10 CCL5 CCL2
39 11.4 STAT2 STAT1 IFNB1 IFIT2 CXCL10
40
Show member pathways
11.2 STAT2 STAT1 IRF3 DDX58
41 11.19 TNF IFNB1 CCL5

GO Terms for Japanese Encephalitis

Biological processes related to Japanese Encephalitis according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.21 TNF TLR3 STAT1 IRF3 IFNB1 DDX58
2 immune system process GO:0002376 10.14 TLR7 TLR3 RSAD2 IRF3 IFIT2 DDX58
3 immune response GO:0006955 10.09 TNF TLR7 TLR3 CXCL10 CCL5 CCL2
4 viral process GO:0016032 10.09 STAT2 STAT1 RSAD2 IVNS1ABP IRF3 DDX58
5 innate immune response GO:0045087 10.08 TLR7 TLR3 RSAD2 IRF3 IFIT2 DDX58
6 inflammatory response GO:0006954 10.06 TNF TLR7 TLR3 CXCL10 CCL5 CCL2
7 regulation of cell proliferation GO:0042127 9.99 TNF STAT2 STAT1 CXCL10
8 cytokine-mediated signaling pathway GO:0019221 9.97 TNF STAT2 STAT1 IFNB1 IFNA1 CXCL10
9 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.96 TRIM52 TNF TLR3 IRF3
10 cellular response to lipopolysaccharide GO:0071222 9.95 TNF IRF3 CXCL10 CCL2
11 cellular response to interferon-gamma GO:0071346 9.91 TLR3 STAT1 CCL5 CCL2
12 positive regulation of interleukin-6 production GO:0032755 9.89 TNF TLR7 TLR3 DDX58
13 positive regulation of inflammatory response GO:0050729 9.88 TNF TLR7 TLR3
14 viral entry into host cell GO:0046718 9.88 CLEC4M CLEC4G CD209
15 cellular response to organic cyclic compound GO:0071407 9.88 TNF STAT1 CCL5 CCL2
16 neutrophil chemotaxis GO:0030593 9.87 CXCL10 CCL5 CCL2
17 chemokine-mediated signaling pathway GO:0070098 9.87 CXCL10 CCL5 CCL2
18 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.87 TNF TLR7 TLR3
19 defense response GO:0006952 9.87 TNF TLR3 STAT2 STAT1 IFNB1 IFNA1
20 positive regulation of interleukin-8 production GO:0032757 9.86 TNF TLR7 TLR3 DDX58
21 positive regulation of interferon-gamma production GO:0032729 9.85 TNF TLR7 TLR3
22 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.85 TNF TLR7 TLR3
23 regulation of protein phosphorylation GO:0001932 9.85 TNF TLR7 STAT2
24 humoral immune response GO:0006959 9.85 TNF IFNB1 IFNA1 CCL2
25 positive regulation of smooth muscle cell proliferation GO:0048661 9.84 TNF STAT1 CCL5
26 negative regulation of viral genome replication GO:0045071 9.83 TNF RSAD2 IFNB1 CCL5
27 protein kinase B signaling GO:0043491 9.82 TNF CCL5 CCL2
28 positive regulation of chemokine production GO:0032722 9.81 TNF TLR7 TLR3
29 positive regulation of interferon-beta production GO:0032728 9.81 TLR7 TLR3 IRF3 DDX58
30 JAK-STAT cascade GO:0007259 9.8 STAT2 STAT1 CCL2
31 leukocyte cell-cell adhesion GO:0007159 9.8 CLEC4M CD209 CCL5
32 lipopolysaccharide-mediated signaling pathway GO:0031663 9.8 TNF IRF3 CCL5 CCL2
33 response to exogenous dsRNA GO:0043330 9.8 TLR3 IRF3 IFNB1 IFNA1 DDX58
34 microglial cell activation GO:0001774 9.79 TNF TLR7 TLR3
35 cellular response to interferon-beta GO:0035458 9.77 TLR3 STAT1 IFNB1
36 cellular response to exogenous dsRNA GO:0071360 9.76 TLR3 IRF3 IFNB1 DDX58
37 viral genome replication GO:0019079 9.74 CLEC4M CD209 CCL2
38 macrophage chemotaxis GO:0048246 9.71 CCL5 CCL2
39 I-kappaB phosphorylation GO:0007252 9.7 TLR7 TLR3
40 type I interferon signaling pathway GO:0060337 9.7 STAT2 STAT1 RSAD2 IRF3 IFNB1 IFNA1
41 positive regulation of viral life cycle GO:1903902 9.69 CLEC4G CD209
42 necroptotic signaling pathway GO:0097527 9.68 TNF TLR3
43 modulation by virus of host morphology or physiology GO:0019048 9.68 CLEC4M CD209
44 cell-cell recognition GO:0009988 9.66 CLEC4M CD209
45 detection of virus GO:0009597 9.65 TLR3 DDX58
46 virion attachment to host cell GO:0019062 9.65 CLEC4M CD209
47 positive regulation of interferon-alpha production GO:0032727 9.65 TLR7 TLR3 STAT1 IRF3 DDX58
48 peptide antigen transport GO:0046968 9.63 CLEC4M CD209
49 response to virus GO:0009615 9.61 TNF TLR3 RSAD2 IVNS1ABP IFNB1 IFIT2
50 defense response to virus GO:0051607 9.4 TRIM52 TLR7 TLR3 STAT2 STAT1 RSAD2

Molecular functions related to Japanese Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.38 TNF TLR7 TLR3 STAT2 STAT1 SPCS1
2 virus receptor activity GO:0001618 9.54 CLEC4M CLEC4G CD209
3 double-stranded RNA binding GO:0003725 9.5 TLR7 TLR3 DDX58
4 virion binding GO:0046790 9.43 CLEC4M CD209
5 chemokine activity GO:0008009 9.33 CXCL10 CCL5 CCL2
6 CCR5 chemokine receptor binding GO:0031730 9.26 STAT1 CCL5
7 mannose binding GO:0005537 9.13 CLEC4M CLEC4G CD209
8 cytokine activity GO:0005125 9.1 TNF IFNB1 IFNA1 CXCL10 CCL5 CCL2

Sources for Japanese Encephalitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....